The association between pretreatment tumor inflammation and the efficacy of BEMPEG + NIVO versus NIVO was evaluated using a four-gene signature, comprised of the following genes: CD274 (PD-L1), CD8A, LAG3, and STAT117 (see “Methods”). This evidence concerns the gene LAG3 and neoplasm.